The efficacy of Gardasil nonavalent HPV vaccine

The best choice of HPV vaccine – Gardasil 4vHPV, Cervatrix 2vHPV or Gardasil 9vHPV – will no doubt vary from one country to another. But decisions regarding the relative cost-effectiveness and affordability of a particular vaccine depend upon estimates of its efficacy. As regards the most recent vaccine, Gardasil 9vHPV, Huh & Luxembourg (H&L) have […]

Read More…

What is the future of cervical screening in the era of HPV vaccination?

With the introduction of HPV child vaccination programmes, there will have to be a shift from cytology to HPV testing as the main technology involved in primary cervical screening, say the contributors to an on-coming special issue of Preventive Medicine (Tota & Ratnam I) (T&R). Why?  Well, first, because of the inevitable decline in the positive […]

Read More…

Where HPV vaccination loses the battle for public support: calculating the health implications for Japan

A recent brief contribution to The Lancet-Oncology (Tanaka & Ueda) uses predictions of the probable health outcomes of the suspension of the Japanese HPV vaccination programme to make the case for an urgent reassessment of the current policy.  This intervention is very timely.  The approved age for HPV vaccination for Japanese girls is a window of four years […]

Read More…

Prevention of anogenital cancers in women may be an additional benefit of HPV vaccination

Cervical cancer is evidently the most important, but by no means the only, health risk that vaccination against HPV aims to avert. The potential impact of vaccination on other cancers (not to mention genital warts) may also be a factor in estimating the cost benefit of achieving higher vaccination coverage, as well as determining priorities […]

Read More…

Mathematical models say: switching to HPV nonavalent vaccine brings cost benefits.

STI journal issues of nearly a decade ago, when HPV vaccination was a relatively new thing, hosted a discussion on the issue of which vaccine to choose. The choice at that time, readers will remember, was between GSK’s Cervarix 2vHPV and Merck’s Gardasil 4vHPV (Morris/STIs)*.  Now, the introduction of a third alternative, Gardasil (9vHPV), seems to […]

Read More…

Population-based study concludes: HPV vaccination does not cause sexual disinhibition

HPV is known to be the cause of various types of cancer, including cervical cancer. Routine vaccination before the onset of sexual activity ought therefore to be effective in reducing the incidence of these cancers, and has been adopted by many countries.  The impact of such programmes will not be apparent for years; but the […]

Read More…

Population-based evidence for the preventative efficacy of quadrivalent HPV in Australia

The HPV vaccination programmes introduced by many countries over the last few years (since 2007) reveal considerable diversity in the coverage they have achieved, the mode of access (i.e. school, public health, private clinics) and responsibility for cost (i.e. publically vv. privately funded) – even in Europe (see ECDC Guidance).  In the light of the […]

Read More…

Sexual health in the post-HPV vaccination era: implications for genital warts and cervical screening

Quadrivalent HPV vaccination (qHPV) for adolescent girls is recommended and publicly financed in a number of countries.  This intervention promises to prevent up to 70% of HPV generated cancers in those vaccinated, as well as vastly reducing the burden of genital warts (GW).  In relation to prevention of HPV generated cancer and cancerous lesions, its […]

Read More…

HPV re-activation in older women: an increased cancer risk unrelated to sexual behaviour?

Older women who have had ≥5 lifetime sexual partners could turn out to be a relatively high-risk group for Human Papilloma Virus (HPV) and associated cervical lesions – regardless of declining sexual activity.  If – that is – Gravitt, Viscidi et al. (http://jid.oxfordjournals.org/content/207/2/272.full.pdf+html?sid=4bc8141c-9b7c-4a13-8a43-451d6fa85fcf; http://jid.oxfordjournals.org/content/207/2/211.full.pdf+html?sid=4bc8141c-9b7c-4a13-8a43-451d6fa85fcf) are correct to see the results of their cohort study of […]

Read More…